Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Sandoz Freshens Up Directors Board After Pivotal Year

As Lantheus Appoints Pharma Veteran As New CEO And Mallinckrodt Adds To Board

Executive Summary

Sandoz nominated a new director candidate ahead of its annual meeting and Lantheus welcomed a familiar face as the new CEO. Meanwhile, Mallinckrodt strengthened its board with four new directors and Hikma announced another appointment this year.

You may also be interested in...



Hikma To Pay Up $150m In US Opioid Settlement Framework

Despite denying any wrongdoing, Hikma joins a group of companies that have agreed to pay big settlements for their alleged respective roles in the ongoing opioid epidemic in the US.

Sandoz Rolls Out Natalizumab Biosimilar In Germany

Sandoz is rolling out its Tyruko natalizumab biosimilar rival to Biogen’s Tysabri in Germany, heralding the product as the “first and only biosimilar for multiple sclerosis.”

Sandoz Plugs Ophthalmology Gap With Coherus Ranibizumab Deal

Sandoz has truly spread its wings since separating from Novartis, striking its first post-spinoff acquisition agreement by taking the Lucentis biosimilar Cimerli from Coherus BioSciences, which is moving in a different strategic direction.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel